<DOC>
	<DOC>NCT01613599</DOC>
	<brief_summary>This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan therapy by their physician according to prescribing information.</brief_summary>
	<brief_title>An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis</brief_title>
	<detailed_description />
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis with Polyangiitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participants, &gt;/= 18 years of age Granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to Chapel Hill Consensus Conference Definitions for MPA and American College of Rheumatology (ACR) Criteria for the Classification of GPA Disease severity requiring rituximab treatment per the investigator's assessment Prior use of rituximab (except if received within 4 weeks of screening) Known hypersensitivity to rituximab, to any component of the product, or to murine proteins Pregnant or breastfeeding women Diagnosis of ChurgStrauss syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>